|
|
Volumn 2, Issue SUPPL. 1, 2008, Pages
|
|
Current approaches for treating chronic hepatitis B: When to start, what to start with, and when to stop
a
|
|
Author keywords
Chronic hepatitis B; Hepatitis B e antigen; Human immunodeficiency virus
|
|
Indexed keywords
ADEFOVIR;
ALANINE AMINOTRANSFERASE;
ALPHA INTERFERON;
ANTIVIRUS AGENT;
CLEVUDINE;
EMTRICITABINE;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ENTECAVIR;
IMMUNOMODULATING AGENT;
LAMIVUDINE;
NUCLEOSIDE;
NUCLEOSIDE ANALOG;
PEGINTERFERON;
PEGINTERFERON ALPHA;
PEGINTERFERON ALPHA2A;
PEGINTERFERON ALPHA2B;
TELBIVUDINE;
TENOFOVIR;
VIRUS DNA;
ANTIVIRAL ACTIVITY;
ANTIVIRAL RESISTANCE;
BONE MARROW SUPPRESSION;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DEPRESSION;
DISEASE COURSE;
DRUG BLOOD LEVEL;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG MEGADOSE;
DRUG POTENTIATION;
DRUG STRUCTURE;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
FLU LIKE SYNDROME;
HEPATITIS B;
HEPATITIS B VIRUS;
HUMAN;
MENTAL DISEASE;
MONOTHERAPY;
NEPHROTOXICITY;
NONHUMAN;
PATIENT ASSESSMENT;
PRIORITY JOURNAL;
REVIEW;
RISK ASSESSMENT;
TREATMENT DURATION;
UNSPECIFIED SIDE EFFECT;
|
|
EID: 69749127481
PISSN: 19360533
EISSN: 19360541
Source Type: Journal
DOI: 10.1007/s12072-008-9059-0 Document Type: Review |
|
Times cited : (5)
|
|
References (46)
|
